Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
To Assess the Safety, Reactogenicity & Immunogenicity of a 4th Dose of GSK Biologicals' Pneumococcal Vaccine or Prevenar™ in Children (12-18 Months) Previously Vaccinated in the Primary Study NCT00307554 With Either Pneumococcal Vaccine or Prevenar™
Sponsor: GlaxoSmithKline
A PHASE3 clinical study on Infections, Streptococcal, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 10 data snapshots since 2006. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Feb 2026 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2019 — Jul 2019 [monthly]
Completed PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Dec 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Sep 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bernay, France , Bydgoszcz, Poland , Colombes, France , Créteil, France , Dax, France , Draguignan, France , Dębica, Poland , Espoo, Finland , Essey-lès-Nancy, France , Helsinki, Finland and 23 more locations